[U.K. - Macugen] Patients Continue To Risk Blindness As NICE Recommends Only Single Therapy In Latest AMD Guidance | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Wednesday, December 19, 2007

Email

Comments

Medical News Today

Pfizer Limited expresses concern that the latest NICE appraisal consultation document (ACD) regarding the use of treatments for wet Age-related Macular Degeneration (AMD), fails to provide any treatment choice for patients or physicians, by recommending only one anti-VEGF therapy for AMD.

Retina Products and Equipment »

The lesion seen below has been present for many years. The patient does not complain of pain, itching or growth. This is most consistent with:
1. apocrine hydrocystoma
2. basal cell carcinoma
3. chronic dacryocystitis
4. sebaceous cell carcinoma
Check The Answer

PanoCam™ LT Wide-field Digital Imaging System
The PanoCam LT represents the first ... view product
Volk iNview
iPhone Fundus Camera The Volk iNview ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us